Current situation and analysis of factors affecting non-mechanical tube blockage during hyperthermic intraperitoneal chemotherapy_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

DENG Yinyong , HE Yuhua , JIANG Lili ,  YANG Jie

Colorectal Cancer Center, West China Hospital, Sichuan University / West China School of Nursing, Sichuan University, Chengdu 610041, P. R. China;

Corresponding?author：

YANG Jie, Email: 645946195@qq.com

Keywords：

hyperthermic intraperitoneal chemotherapy; non-mechanical tube blockage; influencing factor

DOI：

10.7507/1007-9424.202211018

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To understand the current situation and factors affecting tube blockage (non-mechanical) during hyperthermic intraperitoneal chemotherapy (HIPEC). Methods According to the inclusion and exclusion criteria, the patients with malignant tumors who underwent HIPEC in the Department of Gastroenterology of West China Hospital of Sichuan University from May 2019 to May 2021 were retrospectively gathered. The information about the patient and the occurrence of occlusion during HIPEC were obtained by consulting electronic medical records and perfusion records. The logistic regression analysis was performed to analyze the factors influencing non-mechanical tube blockage during HIPEC. Results A total of 240 patients with malignant tumors were gathered. During HIPEC, the non-mechanical tube blockage occurred in 88 patients with malignant tumors, with the incidence of 36.7%. The multivariate analysis results by logistic regression showed that the probabilities of non-mechanical tube blockage during HIPEC were higher in the patients with age≥65 years (OR=2.142, P=0.016), diabetes mellitus (OR=2.326, P=0.007), perfusion speed of 300–450 mL/min (OR=2.778, P=0.001), ascites (OR=2.192, P=0.020), and PCI ≥20 points (OR=4.380, P<0.001). Conclusions Patients with malignant tumors treated with HIPEC are prone to non-mechanical tube blockage. The patients with middle-aged and elderly, diabetes, low perfusion speed, ascites, and high PCI score need to be of great concern, so as to prevent and deal with tube blockage in time.

Citation： DENG Yinyong, HE Yuhua, JIANG Lili, YANG Jie. Current situation and analysis of factors affecting non-mechanical tube blockage during hyperthermic intraperitoneal chemotherapy. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2023, 30(4): 456-459. doi: 10.7507/1007-9424.202211018 Copy

1.	Leebmann H, Piso P. Hyperthermic intraperitoneal chemotherapy. Chirurg, 2019, 90(7): 593-604.
2.	Spratt JS, Adcock RA, Muskovin M, et al. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res, 1980, 40(2): 256-260.
3.	Manzanedo I, Pereira F, Rihuete CC, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer with peritoneal carcinomatosis: multicenter study of Spanish Group of Peritoneal Oncologic Surgery (GECOP). Ann Surg Oncol, 2019, 26(8): 2615-2621.
4.	Auer RC, Sivajohanathan D, Biagi J, et al. Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review. Eur J Cancer, 2020, 127: 76-95.
5.	Marrelli D, Petrioli R, Cassetti D, et al. A novel treatment protocol with 6 cycles of neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in stage Ⅲ primary ovarian cancer. Surg Oncol, 2021, 37: 101523. doi: 10.1016/j.suronc.2021.101523.
6.	Bondar OV, Chetverikov SH, Maksymovskyi VY, et al. The impact of hyperthermic intraperitoneal chemotherapy and cytoreductive surgery on clinical outcomes and quality of life of patients with peritoneal carcinomatosis. Contemp Oncol (Pozn), 2021, 25(4): 270-278.
7.	überrück L, Nadiradze G, Yurttas C, et al. In-hospital mortality and complication rates according to health insurance data in patients undergoing hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies in Germany. Ann Surg Oncol, 2021, 28(7): 3823-3830.
8.	Auer RC, Sivajohanathan D, Biagi J, et al. Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a clinical practice guideline. Curr Oncol, 2020, 27(3): 146-154.
9.	中國抗癌協會腹膜腫瘤專業委員會, 廣東省抗癌協會腫瘤熱療專業委員會. 中國腹腔熱灌注化療技術臨床應用專家共識(2019版). 中華醫學雜志, 2020, 100(2): 89-96.
10.	Birgisson H, Enblad M, Artursson S, et al. Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol, 2020, 46(12): 2283-2291.
11.	Archer AG, Sugarbaker PH, Jelinek JS. Radiology of peritoneal carcinomatosis. Cancer Treat Res, 1996, 82: 263-288.
12.	Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res, 1996, 82: 359-374.
13.	Onaedo I,Marjolein D, Nadine K, et al. Demographic characteristics and outcomes of surveyed community health workers who utilized mobile for mothers [age group]. PLOS One, 2018. doi.org/10.1371/journal.pone.0194927.t007.
14.	中國肥胖問題工作組數據匯總分析協作組. 我國成人體重指數和腰圍對相關疾病危險因素異常的預測價值: 適宜體重指數和腰圍切點的研究. 中華流行病學雜志, 2002, 23(1): 10-15.
15.	詹宏杰, 梁寒. 腹腔熱灌注化療在腹膜癌中的應用現狀. 腫瘤防治研究, 2021, 48(4): 327-332.
16.	Gurusamy K, Vale CL, Pizzo E, et al. Cytoreductive surgery (CRS) with hyperthermic intraoperative peritoneal chemotherapy (HIPEC) versus standard of care (SoC) in people with peritoneal metastases from colorectal, ovarian or gastric origin: protocol for a systematic review and individual participant data (IPD) meta-analyses of effectiveness and cost-effectiveness. BMJ Open, 2020, 10(5): e039314. doi: 10.1136/bmjopen-2020-039314.
17.	中國抗癌協會婦科腫瘤專業委員會, 中國婦科腹腔熱灌注化療技術臨床應用專家協作組. 婦科惡性腫瘤腹腔熱灌注化療臨床應用專家共識(2019). 中國實用婦科與產科雜志, 2019, 35(2): 194-201.
18.	Ljunggren M, Nordenvall C, Palmer G. Direct surgery with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastases. Eur J Surg Oncol, 2021, 47(11): 2865-2872.
19.	朱曉慧, 甄莉, 吳慧琴, 等. 腹腔熱灌注化療過程中管路不通的原因分析及護理. 全科護理, 2018, 16(11): 1367-1369.
20.	梁英, 廖雪梅. 對手術后的卵巢癌患者進行腹腔熱灌注化療時發生循環灌注不暢的原因分析. 當代醫藥論叢, 2019, 17(20): 215-216.
21.	苗凱玲, 李春燕, 侯惠如. 惡性胸腔積液引流管堵塞或引流不暢的影響因素. 武警醫學, 2018, 29(9): 857-860.
22.	桑秀波, 李曉玉, 龔萍, 等. 腫瘤細胞減滅術加腹腔熱灌注化療治療卵巢癌的術后不良事件分析. 臨床腫瘤學雜志, 2022, 27(2): 148-152.
23.	丁平安, 楊沛剛, 田園, 等. 腹腔熱灌注化療在胃癌治療規范化實施中的經驗分享. 腫瘤綜合治療電子雜志, 2021, 7(3): 51-54.
24.	Noiret B, Clement G, Lenne X, et al. Centralization and oncologic training reduce postoperative morbidity and failure-to-rescue rates after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: study on a 10-year National French Practice. Ann Surg, 2020, 272(5): 847-854.
25.	Hübner M, Kusamura S, Villeneuve L, et al. Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC): Enhanced recovery after surgery (ERAS^?) Society Recommendations—Part Ⅰ: preoperative and intraoperative management. Eur J Surg Oncol, 2020, 46(12): 2292-2310.

1. Leebmann H, Piso P. Hyperthermic intraperitoneal chemotherapy. Chirurg, 2019, 90(7): 593-604.
2. Spratt JS, Adcock RA, Muskovin M, et al. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res, 1980, 40(2): 256-260.
3. Manzanedo I, Pereira F, Rihuete CC, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer with peritoneal carcinomatosis: multicenter study of Spanish Group of Peritoneal Oncologic Surgery (GECOP). Ann Surg Oncol, 2019, 26(8): 2615-2621.
4. Auer RC, Sivajohanathan D, Biagi J, et al. Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review. Eur J Cancer, 2020, 127: 76-95.
5. Marrelli D, Petrioli R, Cassetti D, et al. A novel treatment protocol with 6 cycles of neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in stage Ⅲ primary ovarian cancer. Surg Oncol, 2021, 37: 101523. doi: 10.1016/j.suronc.2021.101523.
6. Bondar OV, Chetverikov SH, Maksymovskyi VY, et al. The impact of hyperthermic intraperitoneal chemotherapy and cytoreductive surgery on clinical outcomes and quality of life of patients with peritoneal carcinomatosis. Contemp Oncol (Pozn), 2021, 25(4): 270-278.
7. überrück L, Nadiradze G, Yurttas C, et al. In-hospital mortality and complication rates according to health insurance data in patients undergoing hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies in Germany. Ann Surg Oncol, 2021, 28(7): 3823-3830.
8. Auer RC, Sivajohanathan D, Biagi J, et al. Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a clinical practice guideline. Curr Oncol, 2020, 27(3): 146-154.
9. 中國抗癌協會腹膜腫瘤專業委員會, 廣東省抗癌協會腫瘤熱療專業委員會. 中國腹腔熱灌注化療技術臨床應用專家共識(2019版). 中華醫學雜志, 2020, 100(2): 89-96.
10. Birgisson H, Enblad M, Artursson S, et al. Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol, 2020, 46(12): 2283-2291.
11. Archer AG, Sugarbaker PH, Jelinek JS. Radiology of peritoneal carcinomatosis. Cancer Treat Res, 1996, 82: 263-288.
12. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res, 1996, 82: 359-374.
13. Onaedo I,Marjolein D, Nadine K, et al. Demographic characteristics and outcomes of surveyed community health workers who utilized mobile for mothers [age group]. PLOS One, 2018. doi.org/10.1371/journal.pone.0194927.t007.
14. 中國肥胖問題工作組數據匯總分析協作組. 我國成人體重指數和腰圍對相關疾病危險因素異常的預測價值: 適宜體重指數和腰圍切點的研究. 中華流行病學雜志, 2002, 23(1): 10-15.
15. 詹宏杰, 梁寒. 腹腔熱灌注化療在腹膜癌中的應用現狀. 腫瘤防治研究, 2021, 48(4): 327-332.
16. Gurusamy K, Vale CL, Pizzo E, et al. Cytoreductive surgery (CRS) with hyperthermic intraoperative peritoneal chemotherapy (HIPEC) versus standard of care (SoC) in people with peritoneal metastases from colorectal, ovarian or gastric origin: protocol for a systematic review and individual participant data (IPD) meta-analyses of effectiveness and cost-effectiveness. BMJ Open, 2020, 10(5): e039314. doi: 10.1136/bmjopen-2020-039314.
17. 中國抗癌協會婦科腫瘤專業委員會, 中國婦科腹腔熱灌注化療技術臨床應用專家協作組. 婦科惡性腫瘤腹腔熱灌注化療臨床應用專家共識(2019). 中國實用婦科與產科雜志, 2019, 35(2): 194-201.
18. Ljunggren M, Nordenvall C, Palmer G. Direct surgery with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastases. Eur J Surg Oncol, 2021, 47(11): 2865-2872.
19. 朱曉慧, 甄莉, 吳慧琴, 等. 腹腔熱灌注化療過程中管路不通的原因分析及護理. 全科護理, 2018, 16(11): 1367-1369.
20. 梁英, 廖雪梅. 對手術后的卵巢癌患者進行腹腔熱灌注化療時發生循環灌注不暢的原因分析. 當代醫藥論叢, 2019, 17(20): 215-216.
21. 苗凱玲, 李春燕, 侯惠如. 惡性胸腔積液引流管堵塞或引流不暢的影響因素. 武警醫學, 2018, 29(9): 857-860.
22. 桑秀波, 李曉玉, 龔萍, 等. 腫瘤細胞減滅術加腹腔熱灌注化療治療卵巢癌的術后不良事件分析. 臨床腫瘤學雜志, 2022, 27(2): 148-152.
23. 丁平安, 楊沛剛, 田園, 等. 腹腔熱灌注化療在胃癌治療規范化實施中的經驗分享. 腫瘤綜合治療電子雜志, 2021, 7(3): 51-54.
24. Noiret B, Clement G, Lenne X, et al. Centralization and oncologic training reduce postoperative morbidity and failure-to-rescue rates after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: study on a 10-year National French Practice. Ann Surg, 2020, 272(5): 847-854.
25. Hübner M, Kusamura S, Villeneuve L, et al. Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC): Enhanced recovery after surgery (ERAS^?) Society Recommendations—Part Ⅰ: preoperative and intraoperative management. Eur J Surg Oncol, 2020, 46(12): 2292-2310.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Current situation and analysis of factors affecting non-mechanical tube blockage during hyperthermic intraperitoneal chemotherapy

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content